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Abstract
Background Retinal angiomatous proliferation (RAP) is a
distinct variant of neovascular age-related macular degen-
eration (AMD). The aim of this study is to evaluate the
functional and anatomic outcome after intravitreal ranibi-
zumab (Lucentis) treatment in patients with RAP.
Methods Prospective study of consecutive patients with
newly diagnosed or recurrent RAP treated with intravitreal
ranibizumab at the Jules Gonin Eye Hospital between
March 2006 and December 2007. Baseline and monthly
follow-up visits included best-corrected visual acuity
(BCVA), fundus exam and optical coherence tomography.
Fluorescein and indocyanine green angiography were
performed at baseline and repeated at least every 3 months.
Results Thirty-one eyes of 31 patients were treated with
0.5 mg of intravitreal ranibizumab for RAP between March
2006 and December 2007. The mean age of the patients
was 82.6 years (SD:4.9). The mean number of intravitreal
injections administered for each patient was 5 (SD: 2.4,
range 3 to 12). The mean follow up was 13.4 months (SD:
3, range 10 to 22). The baseline mean logMAR BCVA was
0.72 (SD: 0.45) (decimal equivalent of 0.2). The mean
logMAR BCVA was improved significantly (P<0.0001) at
the last follow-up to 0.45, SD: 0.3 (decimal equivalent
0.35). The visual acuity (VA) improved by a mean of 2.7
lines (SD 2.5). Mean baseline central macular thickness
(CMT) was 376 μm, and decreased significantly to a mean
of 224 μm (P<0.001) at the last follow-up. Mean reduction
of CMT was 152 μm (SD: 58). An average of 81.5% of the
total visual improvement and 85% of the total CMT reduc-
tion occurred during the first post-operative month after one
intravitreal injection of ranibizumab. During follow-up, an
RPE tear occurred in one eye (3.2%) of the study group. No
injection complications or systemic drug-related side-effects
were noted during the follow-up period.
Conclusions Intravitreal ranibizumab injections appeared to
be an effective and safe treatment for RAP, resulting in
visual gain and reduction in macular thickness. Further
long-term studies to evaluate the efficacy of intravitreal
ranibizumab in RAP are warranted.
Keywords Age-related macular degeneration .
Retinal angiomatous proliferation . Ranibizumab
Introduction
Retinal angiomatous proliferation (RAP) is a distinct
variant of neovascular age-related macular degeneration
(AMD) in which, principally, new vessels proliferate within
the neurosensory retina itself (CNV) [1–3]. The typical
clinical presentation of RAP appears to be unique compared
with more common forms of neovascular AMD, represent-
ing 12% to 15% of newly diagnosed patients with neo-
vascular AMD [3, 4].
RAP lesions have been identified as a poor prognostic
factor, and most of the older established treatments did not
seem to alter the natural history of these eyes significantly
[1], in contrast to typical exudative AMD [5]. Various
treatment modalities have been used in the treatment of
RAP, including direct laser photocoagulation, transpupillary
thermotherapy, surgical removal, and photodynamic thera-
py (PDT) with verteporfin (Visudyne; Novartis Pharma
AG, Basel, Switzerland) with or without concomitant intra-
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vitreal triamcinolone [5–22]. However, often their results
were disappointing, leading to limited success or to poor func-
tional results, while in some cases concerns were aroused with
regard to risks of severe complications [5, 16, 17].
It has been reported that RAP lesions demonstrate a
predisposition to vascular endothelial growth factor (VEGF)
expression [23], which consists of diffusible cytokines that
promotes angiogenesis and has been implicated as an
important factor promoting neovascularization [24, 25].
Recently, some studies have reported promising results
with off-label use of the intravitreal anti-VEGF drug beva-
cizumab (AvastinTM, Genentech, South San Francisco, CA,
USA) for the treatment of RAP [26–30], while in 2007 a
study of four patients who presented with RAP reported very
favorable results with use of intravitreal ranibizumab (Lu-
centis®, Genentech, South San Francisco CA, USA) [31].
Ranibizumab is a specific, affinity-mature fragment of a
recombinant, humanized IgG1 monoclonal antibody that
neutralizes all active forms of VEGF-A. It has been found
to be effective in the treatment of exudative age-related
macular degeneration (AMD), demonstrating encouraging
signs of biologic activity, with acceptable safety [32].
The present study evaluated the safety and efficacy of
intravitreal ranibizumab (Lucentis®) in the treatment of RAP.
Patients and methods
Patient selection
This was a retrospective study of 31 consecutive patients
with RAP treated with intravitreal injection of ranibizumab
in the Jules Gonin University Eye Hospital between March
2006 and December 2007. Institutional approval was ob-
tained for this study.
Inclusion criteria were presence of RAP (stage II and III)
on the basis of clinical and fluorescein angiographic
findings according to Yannuzzi et al. [3]; a minimum of
10 months of follow-up, and best-corrected visual acuity
(BCVA) of 2.0 (logMAR) or better.
We excluded from this study patients that had previously
received laser photocoagulation or submacular surgery as
treatment for RAP. Previous PDT treatment was not an
exclusion criterion, on condition that it had been adminis-
tered at least 6 months before Lucentis® treatment.
Furthermore, we excluded patients who presented any
significant ocular disease (other than RAP) that could
compromise vision in the studied eye.
Examination
Patient age, gender, affected eye and any previous treatment
administered were recorded.
The patients were followed every month. Both initial
ophthalmic examination and each follow-up included
evaluation of best-corrected distant and near VA using an
EDTRS chart and a nearpoint Snellen acuity card at 40 cm
respectively; a fundus exam with dilated pupils; fundus
photography; and an evaluation of retinal architecture and
measurement of foveal thickness using the OCT Stratus
(Carl Zeiss Meditec, Inc.). Digital fluorescein angiography
(FA) and indocyanine green (ICG) angiography were
performed at baseline and at least every 3 months. Any
ocular or systemic adverse events also were recorded.
Main indication for retreatment was the presence of any
amount of intraretinal or subretinal fluid shown on OCT.
Persistent activity from RAP lesions shown on FA or ICG
angiograms, such as late leakage on FA or focal areas of
intense hyperfluorescence (hot spots) on ICG, were also
criteria for retreatment.
An informed consent was obtained from all patients after
a thorough discussion before each injection.
Surgical procedure
All injections were performed using the same technique.
Ranibizumab 0.5 mg (0.05 ml) was administered by intra-
vitreal injection under sterile conditions in the operating
theatre. Before injection, tetracaine 0.5% was applied topi-
cally. Povidone iodine was applied to eyelid margins,
eyelashes, and conjunctival surface, and a lid speculum
was placed. An additional drop of povidone iodine was
applied to the site of injection. Using a 30-gauge needle,
0.05 ml ranibizumab was injected 3.5–4.0 mm posterior to
the corneal limbus into the vitreous cavity. The injection site
was compressed with a cotton swab to avoid reflux when
the needle was removed. Postoperatively, a topical antibiotic
(ofloxacin) was administered three times daily for 7 days.
Statistical analysis
The statistical analysis focused on the evaluation of the
change in BCVA and the foveal thickness measured by
OCT before treatment and at the final follow-up, which was
at least 1 month distally to the last ranibizumab treatment.
Additionally, the absence or persistence of RAP activity on
FA, ICG angiography at the final follow-up was evaluated.
BCVA values were converted to logarithm of the minimum
angle of resolution (logMAR) for statistical analysis. To
determine the equivalent mean decimal, logMAR values
were converted back to decimal notation [33].
Serial changes in BCVA and central focal thickness
(CFT) were compared using the two-tailed t-test. A p≤0.05
was considered to be statistically significant.
These parameters were analyzed using SPSS statistical
software (version 16, SPSS Inc., Chicago, IL, USA).
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Results
The study included 31 eyes of 31 patients. There were nine
male (29%) and 22 female (71%) patients. The mean age of
the patients was 82.6 years (SD: 4.9, range 73–92). Mean
time of follow-up was 13.4 months (SD: 3, range 10–
22 months). Eight eyes (26%) had previously received PDT
(mean number of PDT: 2.1, SD: 0.8, range 1–3). The mean
time between last PDT and first treatment with ranibizumab
for these eight patients was 9.6 months (SD: 3.7, range 6–
16 months). The mean number of intravitreal injections
administered for each patient was five (SD: 2.4, range 3–12).
At the time of treatment, 20 eyes (65%) had a stage II
lesion without PED, six (19%) had a stage II lesion with
PED, and five (16%) had a stage III lesion.
A summary of clinical data is shown in Table 1.
Visual acuity
The mean initial VA was 0.2 (decimal equivalent). Mean
logMAR initial VA was 0.72 with a range from 2.0 to 0.4
(SD: 0.45). A statistically significant improvement to a
mean VA of 0.35 decimal equivalent (logMAR 0.45, range:
1.0–0.1, SD: 0.3) was demonstrated at the final follow-up
(p<0.0001, two-tailed t-test). The VA improved by a mean
of 2.7 (SD: 2.5) lines. Fourteen patients (45%) demonstrat-
ed a gain of 3 or more lines. Twenty-eight patients (90%)
showed improvement of VA, while VA remained un-
changed in three patients (10%). No patient had worse
BCVA at the last follow-up than at baseline (Fig. 1). On
average, 81.5% of the total visual improvement occurred
during the first post-operative month after one intravitreal
injection of ranibizumab (logMAR BCVA at month 1: 0.5,
range 1.0–0.1, SD: 0.32) (Fig. 2).
Optical coherence tomography and fluorescein
angiography results
Mean CMT measured with OCT was 376 μm (range 525–
216 μm, SD: 67) at baseline and decreased significantly at
the final follow-up to 224 μm (range 152–358 μm, SD: 51)
(p<0.0001, two-tailed t-test). Average CMT reduction was
Fig. 1 Scattergram showing the baseline logMAR visual acuity and at the
final follow-up after a mean of 13.4months. Note that all patients improved
their visual acuity apart from three, who maintained the pre-operative level
Fig. 2 Scattergram showing the change of mean logMAR best
corrected visual acuity (BCVA) from baseline over time
Characteristics Value P-value
Patients Total 31 (100%)
Males 9 (29%)
Females 22 (71%)
Mean age 82.6 years (SD: 4.9, range: 73–92)
Mean follow-up 13.4 months (SD: 3, range: 10–22)
Mean best-corrected visual acuity Baseline 0.72 (logMAR) (SD: 0.45, range: 2.0–0.4)
Last follow-up 0.2 (decimal equivalent) <0.0001
0.45 (logMAR)
SD: 0.3, range: 0.1–1)
Mean lines gain 0.35 (decimal equivalent) 2.7 (SD 2.5)
Mean central macular thickness Baseline 376 μm (SD: 67, range: 216–525) <0.0001
Last follow-up 224 μm (SD: 51, range 152–358)
Mean reduction 157 μm (SD: 57, range 45–247)
Table 1 Summary of clinical
data
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152 μm (range: 45–247 μm, SD: 58) (Fig. 3). On average,
85% of the total CMT reduction occurred during the first
post-operative month after one intravitreal injection of rani-
bizumab (average CMT reduction at month 1 was 129 μm
0.5, range: 45–221 μm, SD: 54) (Fig. 4).
A reduction of both intraretinal and subretinal fluid was
observed in all cases.
Four (36%) of the 11 eyes that presented PED at pre-
sentation demonstrated a total flattening of the PED after
treatment.
All 31 eyes exhibited diminution or absence of RAP
activity on FA, ICG after treatment, while 20 eyes (64.5%)
showed total absence of signs of angiographic RAP activity
on the final follow-up (Fig. 5). At the final follow-up we
identified five patients (16%) who had not shown any signs
of recurrence for a period of more than 6 months (mean:
6.8 months, SD: 0.8, range: 6–8) after a mean of 4.4
(SD:1.1, range: 3–6) injections. Four of them had a stage II
lesion without PED, and one had a stage II lesion with PED
at baseline.
RAP stage in this study appeared to have no influence in
a statistically significant way on VA improvement or
changes in mean OCT CMT.
Complications
During follow-up, RPE tear occurred in one eye (3.2%) of
the study group which presented a stage II RAP associated
with PED. No injection complications or systemic drug-
related side-effects were noted during the follow-up period.
Discussion
Treatment of RAP is probably the most challenging among
the different forms of neovascular AMD, while various
treatment modalities have been associated with unfavorable
or contradictory results [28]. Extensive, stringent, multi-
center, randomized clinical trials such as the MARINA trial
have shown that ranibizumab provides significant VA
benefit to patients with all angiographic subtypes of CNV
related to AMD (i.e., minimally or predominantly classic,
or occult with no classic component), with a low incidence
of serious ocular and non-ocular adverse events and an ac-
ceptable rate of non-serious adverse events [32, 34]. How-
ever, these studies did not specifically investigate the role
of Lucentis in the treatment of RAP, although the MARINA
trial did not exclude RAP lesions.
Fung et al. in the PrONTO study [35], an open-label,
prospective, single-center, nonrandomized clinical study
reported good anatomical and functional results by OCT-
guided treatment of patients with AMD with intravitreal
ranibizumab. In this study, the authors reported that 25% of
the 40 studied patients had RAP lesions, and required a
higher mean number of ranibizumab treatments compared
with patients with non-RAP lesions. However, the anatom-
ical and functional outcomes of patients with RAP lesions
were not analyzed independently, and consequently the ef-
ficacy of ranibizumab in the treatment of RAP was not
further elucidated.
Lai et al. [31] in a small case series study of four patients
with RAP lesions demonstrated a mean BCVA improve-
ment of 3.0 lines at 3 months, and in addition resolution of
subretinal fluid on OCT examination following ranibizu-
mab injections. Freund et al. [1] reported rapid resolution of
the intraretinal edema, hemorrhage, and neovascular lesion
of three patients with RAP lesions treated with a single
injection of intravitreal ranibizumab.
However, several studies have reported promising short-
term results for the treatment of RAP with off-label use of
the intravitreal anti-VEGF drug bevacizumab; bevacizumab
is approved by the FDA for the treatment of colorectal
cancer. Ghazi et al. [28] reported visual improvement by at
least 2 lines in 61.5% of the patients treated with beva-
Fig. 3 Scattergram showing the pre-operative and post-operative
central macular thickness (CMT) in μm at the final follow-up after a
mean of 13.4 months. Note that all patients reduced their CMT during
the post-operative period
Fig. 4 Scattergram showing the change of mean central macular
thickness (CMT) from baseline over time
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cizumab for RAP lesions. Joeres et al. [30], in their study of
16 eyes with RAP, reported a mean BCVA improvement of
1.7 ± 2 lines 4 weeks after a bevacizumab injection, with
decrease of leakage angiographically in the majority (75%)
of the eyes.
Meyerle et al. [27] reported similar outcomes after beva-
cizumab treatment of RAP, with 94% of 17 treated eyes
having stable or improved vision 3 months after treatment.
On the other hand, in a recent study [36] that inves-
tigated the efficacy of different treatment modalities on
RAP lesions, 13 eyes were treated with ranibizumab. In this
study, the authors report stabilization but not statistically
significant improvement of visual acuity. It is difficult to
explain why the results of this study are so different com-
pared with the other studies, including ours, which used
anti-VEGF treatment.
One important difference, nevertheless, between this and
our study concerns the baseline patient characteristics. In
the above-mentioned study, 61.5% of patients presented
RAP with PED while 65% of our patients had RAP without
PED.
It is additionally worth mentioning that in both the
previous-mentioned and also the present study, FA and ICG
was performed once every 3 months. So OCT solely was
Fig. 5 Selected case: photo
(top row), fluorescein angiogra-
phy (second row), ICG angiog-
raphy (third row) and OCT
(bottom row) of an eye before
(left column) and after (right
column) ranibizumab treatment
for RAP, showing disappearance
of hot spot (arrow) on ICG and
significant improvement of reti-
nal architecture on OCT. BCVA
improved from 0.3 (decimal
equivalent) at the baseline to 0.8
(decimal equivalent) at the final
follow-up 14 months later and
after five injections of
ranibizumab
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used in many instances in order to detect RAP activity and
dictate treatment decisions. One should consider, however,
that OCT (especially in cases of PED) cannot accurately
demonstrate RAP activity, as OCT changes of the PED
itself cannot always be quantified. Consequently, the study
by Rouvas et al. that included a higher percentage of
patients with PED may be biased by a higher percentage of
possible cases of undetected RAP activity, leading to
patients missing treatment.
In our study, a mean VA improvement of 2.7 lines (SD 2.5)
was demonstrated after a mean follow-up of 13.4 months.
Furthermore, an average reduction of 152 μm (SD: 58) of
foveal thickness was documented.
Our results are also relatively similar to those of the
MARINA trial of ranibizumab, suggesting that RAP, while
classically considered as a distinctive subset of exudative
AMD, may respond to ranibizumab treatment in a manner
similar to that for the other types of exudative AMD.
It has been hypothesized that RAP lesions might respond
more rapidly to intravitreal anti-VEGF therapies [1]. This is
in accordance with our results, considering that 81.5% of
the total visual improvement and 85% of the total CMT
reduction occurred during the first post-operative month,
after one intravitreal injection of ranibizumab.
Of our patients, 64.5% showed total absence of signs of
angiographic RAP activity on the final follow-up, while
16% of all cases had not shown any signs of recurrence for
a period of more than 6 months. However, we believe that
ranibizumab treatment may not lead to complete healing of
the RAP lesions, but rather may effectively control RAP
activity with repeated injections over time.
One potential risk to be considered, as has also been
reported by others [37], is the formation of retinal pigment
epithelium (RPE) tears, especially in the presence of
pigment epithelium detachment (PED). One case of RPE
tear (3.2%) was observed in the treated eyes during follow-
up. This prevalence seems to be lower, however, than other
subtypes of exudative AMD, considering that during the
same study period we observed RPE tears in 12.3% of 55
patients presenting a PED associated with occult CNV, and
in 5.4% of 74 eyes presenting a predominantly classic
CNV, after treatment with ranibizumab (unpublished data).
In conclusion, in this small series of eyes with limited
follow-up, intravitreal ranibizumab seems to be a safe and
effective treatment for RAP, resulting in functional and
anatomic improvements. The limitations of this study
include the small number of eyes, the relatively short
follow-up, and the absence of a control group.
In view of the encouraging results from this study,
we consider that randomized, long-term clinical trials
are warranted to determine more accurately the potential
clinical benefit of intravitreal ranibizumab and its safety.
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